- Date Published
- November 2016
NCPDP’s Recommendations for an Integrated, Interoperable Solution to Ensure Patient Safe Use of Controlled Substances
This latest update (2016) to NCPDP’s PDMP white paper includes an Executive Summary overview, and incorporates updates that address the Comprehensive Addiction and Recovery Act (CARA) enhancements for PDMPs and recent feedback from our EDvocacy efforts. NCPDP’s model solution leverages best practices and existing industry standards to enhance state PDMPs, support interoperability, provide real-time reporting and risk alerts, and access to data, giving providers information in a timely manner, across state lines and across pharmacies.
NCPDP Recommendations for Dose Accumulation Monitoring in the Inpatient Setting: Acetaminophen Case Model
This paper provides the healthcare industry, in particular the pharmacy and inpatient facility sectors, with historical and background information on the patient risks associated with hidden sources of acetaminophen and recommendations for best practices to mitigate those risks through facility management and electronic medical record systems.
This white paper appears in the August 1, 2016 issue of the American Journal of Health-System Pharmacy (AJHP). Click here to access the white paper on AJHP’s website.
NCPDP Recommendations for Improving Prescription Drug Monitoring Programs, Version 2
This white paper examines the shortfalls of today’s prescription drug monitoring programs intended to reduce fraud and abuse and proposes a new roadmap for PDMP. The recommendations leverage best practices and NCPDP’s existing, widely adopted standards to help states standardize PDMP’s and provide real-time reporting and access to data, giving providers information in a timely manner, across state lines and across pharmacies.